Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication Effexor XR is indicated in adults for the treatment of: • Major Depressive Disorder (MDD) [see Clinical Studies (14.1) ] • Generalized Anxiety Disorder (GAD) [see Clinical Studies (14.2) ] • Social Anxiety Disorder (SAD) [see Clinical Studies (14.3) ] • Panic Disorder (PD) [see Clinical Studies (14.4) ] Effexor XR is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of adults with:… FDA label
Also known as Effexor XR
Venlafaxine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Venlafaxine MR Capsules 150 | EXPERIMENTAL | Venlafaxine MR Capsules 150 of Dr.Reddy's Laboratories Limited |
| Effexor XR 150 mg Capsules | ACTIVE_COMPARATOR | Effexor XR 150 mg Capsules of Wyeth Laboratories Philadelphia, PA, USA |
| Name | Type | Description |
|---|---|---|
| Venlafaxine | DRUG | Venlafaxine MR Capsules 150 mg |
Inclusion Criteria: Subjects must fulfill all of the following criteria to be considered for inclusion into this study: * Subjects who will provide written informed consent. * Subjects must be healthy human beings within 18-45 years of age (inclusive) weighing at least 50 kg. * Having a Body mass ...
Venlafaxine is a small molecule drug candidate that Dr. Reddy's Laboratories Ltd is developing. It is being studied in a Phase 1 clinical program, with one completed trial in healthy volunteers. The specific medical conditions it is intended to treat have not been publicly disclosed.
Venlafaxine targets SLC6A2 and SLC6A4. It acts as an inhibitor of these targets. SLC6A2 is the norepinephrine transporter and SLC6A4 is the serotonin transporter, so the drug inhibits the reuptake of norepinephrine and serotonin.
Venlafaxine is being developed by Dr. Reddy's Laboratories Ltd, which trades under the ticker RDY. The company is the sponsor of the clinical program for this drug candidate.
Venlafaxine is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug is investigational and has not been approved by the FDA for any indication based on the available development information.
Venlafaxine has been studied in one completed Phase 1 trial, NCT01512459, titled Bioavailability Study of Venlafaxine MR Capsules 150 mg Under Fed Conditions. The trial enrolled 33 healthy adult volunteers in India and used an active-controlled, randomized design without blinding.